Pathena backs TNI’s second round with €3m

Existing investors SHS Gesellschaft für Beteiligungsmanagement and KfW did not participate in the round, but will retain shares.

Pathena was introduced to TNI at a medtech conference - the VC stated it was attracted to the company's product and growing opportunities in the market. 

While Pathena is mainly focused on the IT sector, it plans more investments in medical and healthcare. Antonio Murta, managing partner at Pathena, stated that the GP expects a lot of value to be delivered with upcoming solutions such as patient remote monitoring, early diagnostics and medical clouds.

The financing will be used to conduct clinical trials and obtain regulatory approvals. The founders also hope the fresh capital will enable the market launch of TNI Softflow in Germany and other countries.

Pathena invested via its Pathena Fund, which was launched in May 2013 and closed on €56m. Four investments have been made from it so far.  

Company
Headquartered in Würzburg, TNI develops treatment methods for patients with chronic obstructive pulmonary diseases. These lung diseases include chronic bronchitis, emphysema and chronic obstructive airways disease. Its first product is TNI Softflow, a mobile product for respiratory support.

People
Reinhilde Spatscheck is managing partner at SHS. António Murta is managing partner at Pathena. Ewald Anger is the CEO of TNI. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• Germany